세계의 전립선암 진단약 시장 보고서(2025년)

Prostate cancer diagnostics involve the process of determining and confirming the presence of prostate cancer through diagnostic testing and medical evaluations. The primary aim is to assess the status and severity of the illness, guiding treatment choices. This diagnostic approach is commonly applied in the treatment of prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.

The main products in prostate cancer diagnostics include instruments, reagents and consumables, and accessories. Accessories encompass items in the kit that may not be strictly necessary but can enhance effectiveness, such as a prostate-specific antigen (PSA) test kit, biopsy needle, and ultrasound gel, all utilized in the diagnosis of prostate cancer. Various test types, including preliminary and confirmatory tests, diagnose different types of prostate cancers, such as squamous cell cancer, small cell carcinoma, transitional cell cancer, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, and acinar adenocarcinoma. These diagnostic tests are applicable to various age groups, including adults, pediatric, and geriatric populations, and are performed by different end users, including hospitals, independent diagnostic laboratories, cancer research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The prostate cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer diagnostics market statistics, including prostate cancer diagnostics industry global market size, regional shares, competitors with a prostate cancer diagnostics market share, detailed prostate cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. This prostate cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $4.43 billion in 2024 to $5.02 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to the increasing aging population, advancements in medical imaging, rising awareness and screening programs, public health initiatives, and improved biopsy techniques.

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $8.13 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to the integration of artificial intelligence (AI), growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, and multiparametric MRI for diagnosis. Major trends in the forecast period include liquid biopsy technologies, technological advances in biomarker detection, clinical research and development, digital pathology integration, emergence of multiplex biomarker assays.

The forecast of 12.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. prostate cancer detection by increasing costs for multiparametric Magnetic Resonance Imaging coils and biopsy needles imported from Japan and the Netherlands, potentially leading to delayed diagnoses and higher urology clinic expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The prostate cancer diagnostics market is anticipated to experience growth, driven by the increasing prevalence of prostate cancer. This condition, affecting the prostate gland in the male and female reproductive systems, necessitates early diagnosis through various tests, including prostate-specific antigen (PSA) testing and advanced imaging techniques. In January 2023, the American Cancer Society (ACS) reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths attributed to the disease for the same year. Consequently, the rising prevalence of prostate cancer is expected to fuel the expansion of the prostate cancer diagnostics market.

The growth of the prostate cancer diagnosis market is being driven by an increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending supports the allocation and use of resources for prostate cancer diagnosis, facilitating early detection, accurate staging, and timely intervention, all aimed at improving patient outcomes, survival rates, and the overall quality of care for those affected by prostate cancer. For example, in May 2023, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth of 0.9% in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Thus, the increase in healthcare spending is propelling the growth of the prostate cancer diagnosis market in the future.

Technological innovations represent a prominent trend in the prostate cancer diagnostics market, with major companies introducing advanced AI-powered tools for diagnosis. In March 2023, Qritive, a Singapore-based company, launched QAi Prostate-an AI-powered prostate cancer diagnosis tool designed for pathologists. This tool employs sophisticated machine learning algorithms to identify prostatic adenocarcinoma regions and analyze whole slide images of prostate core needle biopsies. The innovative tool facilitates accurate and swift diagnoses, reducing treatment time.

Strategic partnerships are a key approach adopted by major companies in the prostate cancer diagnostics market to advance cancer precision medicine. In March 2022, Lantheus Holdings Inc., a US-based diagnostic and imaging products company, partnered with Novartis AG, a Switzerland-based pharmaceutical company, to utilize Lantheus' prostate-specific membrane antigen (PSMA) imaging agent, PYLARIFY, in clinical trials for Pluvicto. This collaboration aims to enhance the diagnosis of patients with prostate cancer for improved treatment outcomes.

In August 2022, MDxHealth SA, a US-based precision diagnostics company, acquired Exact Sciences Corporation to bolster its leadership in the precision diagnostics urology market. This acquisition expanded MDxHealth's prostate diagnostics business with the inclusion of the Oncotype DX GPS (Genomic Prostate Score) test. Exact Sciences Corporation, a US-based cancer screening and diagnostic tests company, brought valuable assets, including prostate pipelines software supporting patients throughout their cancer diagnosis and treatment.

Major companies operating in the prostate cancer diagnostics market include F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc, Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc, NeoGenomics Laboratories Inc., Guardant Health Inc, GRAIL Inc, Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd, Exosome Diagnostics Inc., Dana-Farber Cancer Institute, Cellanyx Diagnostics Inc., A3P Biomedical AB

North America was the largest region in the prostate cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prostate cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Products: Instruments; Reagents And Consumables; Accessories
• 2) By Test Type: Preliminary Tests; Confirmatory Tests
• 3) By Prostate Cancer: Squamous Cell Cancer; Small Cell Carcinoma; Transitional Cell Cancer; Prostatic Adenocarcinoma; Ductal Adenocarcinoma; Small Cell Prostate Cancer; Acinar Adenocarcinoma
• 4) By Peer Groups: Adult; Pediatric; Geriatrics
• 5) By End User: Hospitals; Independent Diagnostic Laboratories; Cancer Research Institutes; Other End-Users
• Subsegments:
• 1) By Instruments: Biopsy Instruments; Imaging Devices; Digital Rectal Examination Tools
• 2) By Reagents And Consumables: Diagnostic Assay Kits; Staining Reagents; Sample Collection Materials
• 3) By Accessories: Biopsy Guides; Specimen Handling Accessories; Calibration And Maintenance Tools
• Companies Mentioned: F. Hoffman-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG; Becton Dickinson and Company; Agilent Technologies Inc.; Hologic Inc; Biomerieux SA; Beckman Coulter Inc.; Qiagen N.V.; EXACT Sciences Corporation; Diasorin S.P.A.; OPKO Health Inc.; Myriad Genetics Inc.; Cepheid Inc; NeoGenomics Laboratories Inc.; Guardant Health Inc; GRAIL Inc; Fujirebio Diagnostics Inc.; Ambry Genetics Corporation; MDxHealth SA; Biocept Inc.; Blue Earth Therapeutics Ltd; Exosome Diagnostics Inc.; Dana-Farber Cancer Institute; Cellanyx Diagnostics Inc.; A3P Biomedical AB
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Diagnostics Market Characteristics

3. Prostate Cancer Diagnostics Market Trends And Strategies

4. Prostate Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Prostate Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Diagnostics Total Addressable Market (TAM)

6. Prostate Cancer Diagnostics Market Segmentation

• 6.1. Global Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Instruments
• Reagents And Consumables
• Accessories
• 6.2. Global Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preliminary Tests
• Confirmatory Tests
• 6.3. Global Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Squamous Cell Cancer
• Small Cell Carcinoma
• Transitional Cell Cancer
• Prostatic Adenocarcinoma
• Ductal Adenocarcinoma
• Small Cell Prostate Cancer
• Acinar Adenocarcinoma
• 6.4. Global Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• Geriatrics
• 6.5. Global Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Other End-Users
• 6.6. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Instruments, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy Instruments
• Imaging Devices
• Digital Rectal Examination Tools
• 6.7. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Reagents And Consumables, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Assay Kits
• Staining Reagents
• Sample Collection Materials
• 6.8. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Accessories, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy Guides
• Specimen Handling Accessories
• Calibration And Maintenance Tools

7. Prostate Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Diagnostics Market

• 8.1. Asia-Pacific Prostate Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Diagnostics Market

• 9.1. China Prostate Cancer Diagnostics Market Overview
• 9.2. China Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Diagnostics Market

• 10.1. India Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Diagnostics Market

• 11.1. Japan Prostate Cancer Diagnostics Market Overview
• 11.2. Japan Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Diagnostics Market

• 12.1. Australia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Diagnostics Market

• 13.1. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Diagnostics Market

• 14.1. South Korea Prostate Cancer Diagnostics Market Overview
• 14.2. South Korea Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Diagnostics Market

• 15.1. Western Europe Prostate Cancer Diagnostics Market Overview
• 15.2. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Diagnostics Market

• 16.1. UK Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Diagnostics Market

• 17.1. Germany Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Diagnostics Market

• 18.1. France Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Diagnostics Market

• 19.1. Italy Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Diagnostics Market

• 20.1. Spain Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Diagnostics Market

• 21.1. Eastern Europe Prostate Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Diagnostics Market

• 22.1. Russia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Diagnostics Market

• 23.1. North America Prostate Cancer Diagnostics Market Overview
• 23.2. North America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Diagnostics Market

• 24.1. USA Prostate Cancer Diagnostics Market Overview
• 24.2. USA Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Diagnostics Market

• 25.1. Canada Prostate Cancer Diagnostics Market Overview
• 25.2. Canada Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Diagnostics Market

• 26.1. South America Prostate Cancer Diagnostics Market Overview
• 26.2. South America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Diagnostics Market

• 27.1. Brazil Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Diagnostics Market

• 28.1. Middle East Prostate Cancer Diagnostics Market Overview
• 28.2. Middle East Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Diagnostics Market

• 29.1. Africa Prostate Cancer Diagnostics Market Overview
• 29.2. Africa Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Diagnostics Market Competitive Landscape
• 30.2. Prostate Cancer Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffman-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Becton Dickinson and Company
• 31.2. Agilent Technologies Inc.
• 31.3. Hologic Inc
• 31.4. Biomerieux SA
• 31.5. Beckman Coulter Inc.
• 31.6. Qiagen N.V.
• 31.7. EXACT Sciences Corporation
• 31.8. Diasorin S.P.A.
• 31.9. OPKO Health Inc.
• 31.10. Myriad Genetics Inc.
• 31.11. Cepheid Inc
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Guardant Health Inc
• 31.14. GRAIL Inc
• 31.15. Fujirebio Diagnostics Inc.

32. Global Prostate Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Diagnostics Market

34. Recent Developments In The Prostate Cancer Diagnostics Market

35. Prostate Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer